GBG Forschungs GmbH (German Breast Group)

AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2019 (2019) Ditsch N, Untch M, Thill M, Müller V, Janni W, Albert US, Bauerfeind I, et al. Journal article Mutational diversity and therapy response in breast cancer: A sequencing analysis in the neoadjuvant geparsepto trial (2019) Loibl S, Treue D, Budczies J, Weber K, Stenzinger A, Schmitt WD, Weichert W, et al. Journal article Fatal events during clinical trials: an evaluation of deaths during breast cancer studies (2019) Furlanetto J, von Minckwitz G, Lederer B, Möbus V, Schneeweiss A, Huober J, Fasching P, et al. Journal article Diagnosis and Therapy of Triple-Negative Breast Cancer (TNBC) - Recommendations for Daily Routine Practice (2019) Schneeweiss A, Denkert C, Fasching P, Fremd C, Gluz O, Kolberg-Liedtke C, Loibl S, Lück HJ Journal article Concerning Dediu M, Zielinski A: A Proposal to Redefine Pathologic Complete Remission as Endpoint following Neoadjuvant Chemotherapy in Early Breast Cancer. Breast Care 2019; Doi 10.1159/000500620 (2019) Untch M, Loibl S, Fasching P Journal article, Letter Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto—GBG 84): A randomised phase III trial (2019) Schneeweiss A, Moebus V, Tesch H, Hanusch C, Denkert C, Luebbe K, Huober J, et al. Journal article Clinical and analytical validation of Ki-67 in 9069 patients from IBCSG VIII + IX, BIG1-98 and GeparTrio trial: systematic modulation of interobserver variance in a comprehensive in silico ring trial (2019) Denkert C, Budczies J, Regan MM, Loibl S, Dell’Orto P, von Minckwitz G, Mastropasqua MG, et al. Journal article Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial (2019) Janning M, Müller V, Vettorazzi E, Cubas-Cordova M, Gensch V, Ben-Batalla I, zu Eulenburg C, et al. Journal article Impact of nab-paclitaxel dose reduction on survival of the randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy of weekly nab-paclitaxel (nP) with solvent-based paclitaxel (P) followed by anthracycline/cyclophosphamide for patients with early breast cancer (BC) (2018) Untch M, Jackisch C, Schneeweiss A, Schmatloch S, Aktas B, Denkert C, Schem C, et al. Conference contribution Evaluation of the MammaTyperVR as a molecular predictor for pathological complete response (pCR) after neoadjuvant chemotherapy (NACT) and outcome in patients with different breast cancer (BC) subtypes (2018) Fasching P, Laible M, Weber KE, Wirtz RM, Denkert C, Schlombs K, Schmatloch S, et al. Conference contribution